Mirjam Gauri Winkel

Mirjam Gauri Winkel

Auto-generated profile, based on publicly available information

Mirjam Gauri Winkel

University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDPhilipp Doldi
Philipp Doldi
LSLukas Stolz
Lukas Stolz
MOMathias Orban
Mathias Orban
NKNicole Karam
Nicole Karam
FPFabien Praz
Fabien Praz
JHJörg Hausleiter
Jörg Hausleiter

28 October 2024 in JACC
Verified
Journal Article
Closed access
MWMirjam G. Wild
Mirjam G. Wild
LSLukas Stolz
Lukas Stolz
SRSebastian Rosch
Sebastian Rosch
FRFelix Rudolph
Felix Rudolph
BGBjörn Goebel
Björn Goebel
CPChristoph Pauschinger
Christoph Pauschinger

28 December 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
LSLukas Stolz
Lukas Stolz
PDPhilipp Doldi
Philipp Doldi
MOMathias Orban
Mathias Orban
NKNicole Karam
Nicole Karam
TPTania Puscas
Tania Puscas
JHJörg Hausleiter
Jörg Hausleiter

1 February 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GMGuillem Muntané-Carol
Guillem Muntané-Carol
MTMaurizio Taramasso
Maurizio Taramasso
MMMizuki Miura
Mizuki Miura
MGMara Gavazzoni
Mara Gavazzoni
APAlberto Pozzoli
Alberto Pozzoli
JRJosep Rodés-Cabau
Josep Rodés-Cabau
Background: Scarce data exist on patients with right ventricular dysfunction (RVD) or pulmonary hypertension (PH) undergoing transcatheter tricuspid valve intervention. This study aimed to determine the early and midterm outcomes and the factors associated with mortality in this group of patients. Methods: This subanalysis of the multicenter TriValve (Transcatheter Tricuspid Valve Therapies) registry included 300 patients with severe tricuspid regurgitation with RVD (n=244), PH (n=127), or both (n=71) undergoing transcatheter tricuspid valve intervention. RVD was defined as a tricuspid annular plane systolic excursion <17 mm, and PH as an estimated pulmonary artery systolic pressure ≥50 mm Hg. Results: Mean age of the patients was 77±9 years (54% women). Procedural success was 80.7%, and 9 patients (3%) died during the hospitalization. At a median follow-up of 6 (interquartile range, 2–12) months, 54 patients (18%) died, and the independent associated factors were higher gamma-glutamyl transferase values at baseline (hazard ratio, 1.02 for each increase of 10 u/L [95% CI, 1.002–1.04]), poorer renal function defined as an estimated glomerular filtration rate <45 mL/min (hazard ratio, 2.3 [95% CI, 1.22–4.33]), and the lack of procedural success (hazard ratio, 2.11 [95% CI, 1.17–3.81]). The grade of RVD and the amount of PH at baseline were not found to be predictors of mortality. Most patients alive at follow-up improved their functional class (New York Heart Association I–II in 66% versus 7% at baseline, P <0.001). Conclusions: In patients with severe tricuspid regurgitation and RVD/PH, transcatheter tricuspid valve intervention was associated with high procedural success and a relatively low in-hospital mortality, along with significant improvements in functional status. However, about 1 out of 5 patients died after a median follow-up of 6 months, with hepatic congestion, renal dysfunction, and the lack of procedural success determining an increased risk. These results may improve the clinical evaluation of transcatheter tricuspid valve intervention candidates and would suggest a closer follow-up in those at increased risk. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03416166.

4 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
Leor PerlLeor Perl
Leor Perl
MKMark Kheifets
Mark Kheifets
AGAscione Guido
Ascione Guido
EAEustachio Agricola
Eustachio Agricola
PDPaolo Denti
Paolo Denti
GMGiulia Masiero
Giulia Masiero
Background: Little is known about the impact of transcatheter mitral valve edge‐to‐edge repair on changes in left ventricular ejection fraction (LVEF) and the effect of an acute reduction in LVEF on prognosis. We aimed to assess changes in LVEF after transcatheter mitral valve edge‐to‐edge repair for both primary and secondary mitral regurgitation (PMR and SMR, respectively), identify rates and predictors of LVEF reduction, and estimate its impact on prognosis. Methods and Results: In this international multicenter registry, patients with both PMR and SMR undergoing transcatheter mitral valve edge‐to‐edge repair were included. We assessed rates of acute LVEF reduction (LVEFR), defined as an acute relative decrease of >15% in LVEF, its impact on all‐cause mortality, major adverse cardiac event (composite end point of all‐cause death, mitral valve surgery, and residual mitral regurgitation grade ≥2), and LVEF at 12 months, as well as predictors for LVEFR. Of 2534 patients included (727 with PMR, and 1807 with SMR), 469 (18.5%) developed LVEFR. Patients with PMR were older (79.0±9.2 versus 71.8±8.9 years; P <0.001) and had higher mean LVEF (54.8±14.0% versus 32.7±10.4%; P <0.001) at baseline. After 6 to 12 months (median, 9.9 months; interquartile range, 7.8–11.9 months), LVEF was significantly lower in patients with PMR (53.0% versus 56.0%; P <0.001) but not in patients with SMR. The 1‐year mortality was higher in patients with PMR with LVEFR (16.9% versus 9.7%; P <0.001) but not in those with SMR ( P =0.236). LVEF at baseline (odds ratio, 1.03 [95% CI, 1.01–1.05]; P =0.002) was predictive of LVEFR for patients with PMR, but not those with SMR ( P =0.092). Conclusions: Reduction in LVEF is not uncommon after transcatheter mitral valve edge‐to‐edge repair and is correlated with worsened prognosis in patients with PMR but not patients with SMR. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05311163.

28 October 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
LSLukas Stolz
Lukas Stolz
KKKarl-Patrik Kresoja
Karl-Patrik Kresoja
JSJennifer von Stein
Jennifer von Stein
VFVera Fortmeier
Vera Fortmeier
BKBenedikt Koell
Benedikt Koell
CGCristina Giannini
Cristina Giannini
Data regarding the association of pulmonary hypertension (PH) and outcomes in patients undergoing transcatheter tricuspid valve edge-to-edge repair (T-TEER) are scarce. To 1) investigate the impact of PH on outcomes after T-TEER and 2) to shed further light into the role of pre- and postcapillary PH in patients undergoing T-TEER for relevant tricuspid regurgitation (TR). The study included patients from the EuroTR registry (NCT06307262) who underwent T-TEER for relevant TR from 2016 until 2023 with available invasive evaluation of sPAP using right heart catheterization. Study endpoints were procedural TR reduction, improvement in New York Heart Association (NYHA) function class and a combined endpoint of death or heart failure hospitalization (HFH) at two-years. Among a total of 1230 patients (mean age 78.6 ±7.0 years; 51.4% women) increasing systolic pulmonary artery pressure (sPAP) was independently associated with increasing rates of two-year death or HFH (hazard ratio 1.027, 95% confidence interval 1.003-1.052, p=0.030; median survival follow up 343 (114-645) days). No significant survival differences were observed for patients with pre- vs. postcapillary PH. Sensitivity analysis revealed a sPAP value of 46 mmHg as optimized threshold for prediction of death or HFH. Being observed in 526 patients (42.8%), elevated sPAP > 46 mmHg was associated with more severe heart failure symptoms at baseline and follow-up. Importantly, NYHA functional class and TR severity significantly improved irrespective of PH. PH is an important outcome predictor in patients undergoing T-TEER for relevant TR. In contrast to previous studies, no significant differences were observed for patients with pre- and postcapillary PH in terms of survival free from HFH.